GAITHESBURG, MD – Seegene Inc., a multiplex molecular diagnostic technology developer, announced July 2, 2012 the introduction of Quantplex MTB/MDR/XDR Detection. The technology is a real-time test for the detection of Mycobacterium tuberculosis and resistance mutations associated with multiple drug resistant (MDR) and extensively drug resistant (XDR) forms of M. tuberculosis. The announcement was made at the 2012 American Association of Clinical Chemistry (AACC) annual meeting in Los Angeles.
The test is based on enhancements to the company’s TOCE technology, called Cleavage Site Specific Extension (TOCE-CSSE), enabling high multiplex mutation detection of disease. It is a first-in-class diagnostic test that can detect the presence of M. tuberculosis and determine if any of the eighteen rifampicin or seven isoniazid resistance mutations are present. The assay can also determine the presence of seven quinolone resistant mutations and six resistance mutations to injectable drugs.

iConnectHub
Login/Register
Supplier Login















